Kestra Medical Technologies (NASDAQ:KMTS) Price Target Raised to $32.00

Kestra Medical Technologies (NASDAQ:KMTS) had its target price hoisted by BTIG Research from $30.00 to $32.00 in a research report report published on Wednesday morning, Marketbeat Ratings reports. They currently have a buy rating on the stock.

KMTS has been the topic of several other research reports. Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a report on Wednesday. The Goldman Sachs Group lowered their price target on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Wall Street Zen upgraded Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Finally, Weiss Ratings raised Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 30th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Kestra Medical Technologies has a consensus rating of “Hold” and an average target price of $27.83.

Kestra Medical Technologies Trading Up 1.8%

Shares of KMTS stock opened at $24.42 on Wednesday. Kestra Medical Technologies has a 12 month low of $14.10 and a 12 month high of $30.00. The company has a market cap of $1.43 billion, a PE ratio of -10.09 and a beta of 0.47. The company has a quick ratio of 7.32, a current ratio of 4.41 and a debt-to-equity ratio of 0.16. The business’s 50 day moving average is $22.28 and its two-hundred day moving average is $22.72.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). The firm had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. Equities analysts predict that Kestra Medical Technologies will post -2.3 EPS for the current year.

Insider Buying and Selling

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $20.81, for a total value of $312,150.00. Following the completion of the sale, the insider directly owned 395,467 shares of the company’s stock, valued at $8,229,668.27. This represents a 3.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Farther Finance Advisors LLC acquired a new stake in Kestra Medical Technologies during the fourth quarter worth about $31,000. Russell Investments Group Ltd. raised its holdings in Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after acquiring an additional 474 shares in the last quarter. Daiwa Securities Group Inc. bought a new stake in shares of Kestra Medical Technologies in the 4th quarter worth approximately $72,000. BNP Paribas Financial Markets grew its holdings in shares of Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after purchasing an additional 1,638 shares in the last quarter. Finally, Brown Brothers Harriman & Co. grew its holdings in shares of Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after purchasing an additional 656 shares in the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.